Is Phreesia, Inc. (NYSE:PHR) The Top Stock With Improving Technical Ratings According To Piper Sandler?
Down -10.25% in 4 Weeks, Here's Why Phreesia (PHR) Looks Ripe for a Turnaround
Phreesia Joins the Network Advertising Initiative as a Member, Demonstrating Ongoing Commitment to Industry-Leading Privacy Practices
Phreesia and Ad Council Partnership Yields High Patient Engagement in 3 Mental Health Awareness Campaigns
Phreesia Rises After New Contract
Express News | Phreesia: Contract With CMS Innovation Center (Cmmi) for Use of Patient Activation Measure® (PAM) Has Been Renewed Through 2029
Phreesia Secures New Contract With CMS as Report Shows Gains in Patient Activation in First Year of Kidney Care Choices (KCC) Model
RBC Capital Maintains Phreesia(PHR.US) With Hold Rating, Maintains Target Price $23
Is Phreesia (NYSE:PHR) A Risky Investment?
Barclays Maintains Phreesia(PHR.US) With Buy Rating, Maintains Target Price $29
Phreesia (PHR) Gets a Buy From Barclays
Phreesia Exec Sells Over $2,300 in Stock Amid Mandatory Policy
New Research Shows Point-of-Care Patient Outreach Supports Vaccine Confidence and Adoption
CDC Awards Grant to NAFC, Phreesia and Health.Equity.Outcomes. to Tackle Public Health Challenge of Urinary Incontinence
Phreesia (PHR) Improves Healthcare Outcomes and Expects Growing Clientele
Phreesia Analyst Ratings
J.P. Morgan Maintains Phreesia(PHR.US) With Buy Rating, Raises Target Price to $28
Truist Financial Maintains Phreesia(PHR.US) With Buy Rating, Announces Target Price $31
Baird Maintains Phreesia(PHR.US) With Buy Rating, Raises Target Price to $34
A Quick Look at Today's Ratings for Phreesia(PHR.US), With a Forecast Between $30 to $34